| Status |
Official Title |
Lead Investigator |
Last Updated |
| Finalised |
Utilisation of Dulaglutide in European Countries: A Cross-Sectional, Multi-Country and Multi-Source Drug Utilisation Study Using Electronic Health Record Databases |
Dr Ayad Ali |
02/11/2020 |
| Finalised |
Drug Utilisation Study of conjugated oestrogens/ bazedoxifene (CE/BZA) in the European Union (EU) |
Dr Vera Frajzyngier |
14/05/2020 |
| Finalised |
Drug Utilization Study of Thiocolchicoside (TCC) containing medicinal products for systemic |
Mrs Intissar Bourahla |
05/03/2020 |
| Finalised |
Drug Utilisation Study for Olodaterol |
Dr Alicia Gilsenan |
21/01/2020 |
| Finalised |
Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2018 Bi-annual assessment report |
Dr Kristin Meyers |
11/03/2019 |
| Finalised |
Evaluation of the Effectiveness of Risk Minimization Measures: Trimetazidine Drug Utilization Study in European Countries using databases – analysis for France, Hungary, Romania and Spain |
Dr Toussi Massoud |
11/03/2019 |
| Finalised |
Severe hypersensitivity reactions associated with high dose iv iron containing medicinal products |
Dr Gohlke Annegret |
01/03/2019 |
| Finalised |
Drug Utilization Study for azilsartan medoxomil in Germany |
Dr Birgit Ehlken |
28/02/2019 |
| Finalised |
Patient real-world clinical, neurological, tolerability, and safety outcomes for Tecfidera® and Rebif®: A retrospective study (PROTRACT) |
Dr Gabriele Haas |
23/10/2018 |
| Finalised |
Drug utilization study for Elvanse® / Tyvense® in Europe |
Dr Dorothea von Bredow |
10/10/2018 |
| Finalised |
European Drug Usage Survey for Amyvid (I6E-MC-AVBF) |
Dr Claudia Salinas |
12/07/2018 |
| Finalised |
Drug utilisation study (DUS) on flupirtine-containing medicinal products |
Dr Toussi Massoud |
03/04/2018 |
| Finalised |
Drug utilisation study (DUS) on flupirtine-containing products Retrospective drug utilisation study using patient-level databases to characterise prescribing practices of flupirtine-containing drugs during routine clinical use and assess the main reasons for prescription by representative groups of prescribers |
Dr Toussi Massoud |
30/03/2018 |
| Finalised |
Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey and Drug Utilisation Study among Health Care Professionals to Assess their Knowledge and Attitudes on Prescribing Conditions of valproate in France, Germany, Spain, Sweden and United Kingdom |
Dr Toussi Massoud |
28/03/2018 |
| Finalised |
Post-Authorisation Safety Study (PASS) for Flupirtine – Effect of Risk Minimisation Measures in Germany |
Dr Dorothea von Bredow |
28/03/2018 |
| Finalised |
Drug utilisation study (DUS) on flupirtine-containing medicinal products |
Professor Karel Kostev |
23/03/2018 |
| Finalised |
Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey among Health Care Professionals to Assess their Knowledge and Attitudes on Prescribing Conditions of Thiocolchicoside containing Medicinal Products for Systemic Use in France, Greece, Italy and Portugal |
Dr Toussi Massoud |
09/03/2018 |
| Finalised |
A Drug Utilisation Study of Domperidone in Europe Using Databases |
Ms Oliveria Susan |
25/01/2018 |
| Finalised |
Testing new approaches to monitoring benefit/risk with pertussis vaccines as test case: Incidence rates of pertussis and pertussis related outcomes of whole-cell pertussis and acellular pertussis vaccines in pre-school children |
Professor Miriam Sturkenboom |
27/11/2017 |
| Finalised |
Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2014 Bi-annual assessment report |
Dr Kellier Nicole |
10/08/2017 |
| Finalised |
Monitoring of Compliance with Exenatide Prescribing Guidelines in Canada: Drug Utilisation Study of BYETTA in Canada for 2011-2014 |
Dr Sarah Frise |
11/05/2017 |
| Finalised |
Evaluation of the Effectiveness of Risk Minimisation Measures: A Joint PASS Survey among Health Care Professionals to Assess their Knowledge and Attitudes on Prescribing Conditions of Trimetazidine in Bulgaria, Czech Republic, Estonia, France, Hungary, Latvia, Lithuania, Poland, Portugal, Romania, Slovakia, and Spain |
Dr Toussi Massoud |
28/04/2017 |
| Finalised |
Observational single-cohort data base study of dapagliflozin utilisation in Europe |
Mrs Joelle Asmar |
10/04/2017 |
| Finalised |
Drug utilisation study, in five European countries, using cross sectional analysis, to assess the extent of prescriptions of trimetazidine for its withdrawn ophthalmological and ENT indications among general practitioners, ophthalmologists and ENT specialists |
Dr Toussi Massoud |
02/03/2017 |
| Finalised |
Prevalence and Incidence of Problematic Prescription Opioid Use and Abuse in the United Kingdom and Germany |
Dr Joseph Kim |
27/02/2017 |
| Finalised |
Drug Utilization Study of ZALTRAP® (aflibercept) Using European Databases |
Dr Vernon Schabert |
16/12/2016 |
| Finalised |
Assessment of the effectiveness of risk minimisation measures set up for new safety information for Efient® (Prasugrel): a multinational survey among physicians to evaluate their knowledge and consideration of the new safety warning for Prasugrel in four European countries |
Dr Toussi Massoud |
13/10/2016 |
| Finalised |
Strattera patient exposures and adherence in the United Kingdom, Germany, the Netherlands, and Sweden: 2016 Bi-annual assessment report. |
Dr Meyers Kristin |
19/08/2016 |
| Finalised |
Assessment of the safety of LABAs in asthma in routine care by combining healthcare databases and direct patient follow-up |
Dr Eric VAN GANSE |
29/07/2016 |
| Ongoing |
Drug utilisation study of Intuniv® (guanfacine extended release) in European Countries – A prescriber survey |
Dr Dorothea von Bredow |
05/05/2020 |
| Ongoing |
Drug Utilisation Study of Intuniv® (guanfacine extended release) in European Countries, Study protocol I: Database study |
Dr Dorothea von Bredow |
05/05/2020 |
| Ongoing |
An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Among Patients Aged 18 Years and Older Diagnosed with Non Cancer Pain and Treated with Opioids Chronically |
Dr Javier Cid |
14/02/2017 |
| Ongoing |
An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Drug Utilization in Selected European Populations |
Dr Javier Cid |
14/02/2017 |
| Planned |
Drug utilization of Intrarosa (6.5 mg prasterone pessary) in European Countries |
Dr Marlene Montesino |
30/07/2020 |
| Planned |
Assessment of Health Care Professionals’ Knowledge and Behaviour Regarding Prescribing Conditions of Cholib® (fenofibrate and simvastatin fixed combination): A European PASS conducted in Austria, Portugal, Slovenia, Croatia, Greece and Bulgaria |
Dr Toussi Massoud |
18/03/2020 |
| Planned |
EVALUATION OF THE EFFECTIVENESS OF RISK MINIMISATION MEASURES: A SURVEY AMONG HEALTH CARE PROFESSIONALS AND PATIENT/CAREGIVERS TO ASSESS THEIR KNOWLEDGE AND ATTITUDES ON PRESCRIBING AND HOME ADMINISTRATION CONDITIONS OF VELAGLUCERASE ALPHA (VPRIV®) IN 6 EUROPEAN COUNTRIES |
Dr Toussi Massoud |
19/09/2017 |
| Planned |
Drug utilisation study (DUS) on the use of Cholib® (fenofibrate and simvastatin fixed combination): a European multinational study using secondary health records databases |
Dr Toussi Massoud |
13/10/2016 |
